The economic value of a visceral leishmaniasis vaccine in Bihar State, India

Bruce Y. Lee, Kristina M. Bacon, Mirat Shah, Sarah Beth Kitchen, Diana L. Connor, Rachel B. Slayton

Research output: Contribution to journalArticlepeer-review

39 Scopus citations


Visceral leishmaniasis (VL) is responsible for substantial morbidity and mortality and current available treatments have many limitations. The ability of VL infection to generate life-long immunity offers promise for the development of a VL vaccine. A VL vaccine candidate has recently completed phase I clinical trials. We constructed a computer simulation model to determine the potential economic value of a VL vaccine in the endemic region of Bihar state, India. Results found a potential vaccine to be cost-effective (and in many cases economically dominant, i.e., saving costs and providing health benefits) throughout a wide range of vaccination costs, vaccine efficacies, and VL risks. Overall, our study strongly supports the continued development of a VL vaccine.

Original languageEnglish (US)
Pages (from-to)417-425
Number of pages9
JournalAmerican Journal of Tropical Medicine and Hygiene
Issue number3
StatePublished - Mar 2012
Externally publishedYes

ASJC Scopus subject areas

  • Parasitology
  • Virology
  • Infectious Diseases


Dive into the research topics of 'The economic value of a visceral leishmaniasis vaccine in Bihar State, India'. Together they form a unique fingerprint.

Cite this